Adults age ≥ 18 with TP53-mutated AML or MDS who were suitable candidates for first allo-HSCT and were in morphologic CR/CRi/CRp prior to maintenance initiation with engraftment (ANC ≥ 500, PLT > 20,000). This evidence concerns the gene TP53 and myelodysplastic syndrome.